The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Fiche publication
Date publication
janvier 2016
Journal
Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
Tous les auteurs :
Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, Gadea E, Abrial C, Thivat E, Chollet P, Eymard JC
Lien Pubmed
Résumé
Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC).
Mots clés
Adenocarcinoma, drug therapy, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Chromogranin A, blood, Curcumin, administration & dosage, Geriatric Assessment, Humans, Male, Medication Adherence, Middle Aged, Phosphopyruvate Hydratase, blood, Pilot Projects, Prednisone, administration & dosage, Prostate-Specific Antigen, blood, Prostatic Neoplasms, Castration-Resistant, blood, Survival Rate, Taxoids, administration & dosage, Treatment Outcome
Référence
Oncology. 2016 ;90(2):69-78